172 related articles for article (PubMed ID: 31385526)
1. Long-term disease control and high clinical benefit in a patient with advanced thyroid cancer treated with lenvatinib.
Muratori L; Sperone P; Scagliotti GV
Future Oncol; 2019 Aug; 15(24s):3-6. PubMed ID: 31385526
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the QTc interval during lenvatinib treatment in radioiodine-refractory differentiated thyroid cancer: reports from the real-life clinical practice.
Marina M; Serra MF; Rio PD; Ceresini G
Future Oncol; 2019 Aug; 15(24s):7-12. PubMed ID: 31418590
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
4. Embolization of iliac metastasis during lenvatinib treatment in patient with advanced Hürthle cell thyroid carcinoma.
Rodia R; Marini S; Pani F; Boi F; Mariotti S
Future Oncol; 2019 Aug; 15(24s):35-40. PubMed ID: 31385535
[TBL] [Abstract][Full Text] [Related]
5. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
[TBL] [Abstract][Full Text] [Related]
6. Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma.
Gay S; Monti E; Trambaiolo Antonelli C; Mora M; Spina B; Ansaldo G; Teliti M; Comina M; Conte L; Minuto M; Varaldo E; Zupo S; Massa B; Morbelli S; Giusti M
Future Oncol; 2019 Aug; 15(24s):13-19. PubMed ID: 31385546
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
8. Management of one patient with oligoprogressive thyroid cancer during treatment with lenvatinib.
Porcelli T; Sessa F; Gambale C; Luongo C; Salvatore D
Future Oncol; 2019 Aug; 15(24s):21-25. PubMed ID: 31411063
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review.
Sheu NW; Jiang HJ; Wu CW; Chiang FY; Chiou HC; Hsiao PJ
World J Surg Oncol; 2019 May; 17(1):84. PubMed ID: 31103041
[TBL] [Abstract][Full Text] [Related]
10. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.
Tori M; Shimo T
BMC Cancer; 2018 Jun; 18(1):698. PubMed ID: 29954369
[TBL] [Abstract][Full Text] [Related]
12. Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report.
Kitamura M; Hayashi T; Suzuki C; Hirano S; Tateya I; Kishimoto Y; Omori K
World J Surg Oncol; 2017 Jan; 15(1):24. PubMed ID: 28088233
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
Fleeman N; Houten R; Chaplin M; Beale S; Boland A; Dundar Y; Greenhalgh J; Duarte R; Shenoy A
BMC Cancer; 2019 Dec; 19(1):1209. PubMed ID: 31830943
[TBL] [Abstract][Full Text] [Related]
14. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
[TBL] [Abstract][Full Text] [Related]
15. Control of Lung Metastases and Colon Polyposis with Lenvatinib Therapy in a Patient with Cribriform-Morular Variant of Papillary Thyroid Carcinoma and an
Ito Y; Ishikawa H; Kihara M; Hirokawa M; Kiyota N; Kasahara T; Miyauchi A
Thyroid; 2019 Oct; 29(10):1511-1517. PubMed ID: 31317827
[No Abstract] [Full Text] [Related]
16. [Effectiveness of Lenvatinib for Thyroid Cancer with Lung Metastases - Report of a Case].
Nagashima S; Matsuo S; Takahashi M; Umemoto Y; Hirano T; Enomoto K; Sakurai K; Amano S
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2121-2123. PubMed ID: 28133242
[TBL] [Abstract][Full Text] [Related]
17. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib: first global approval.
Scott LJ
Drugs; 2015 Apr; 75(5):553-60. PubMed ID: 25795101
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report.
Latorre A; Fioretti AM; Giotta F; Lorusso V
Future Oncol; 2019 Aug; 15(24s):27-33. PubMed ID: 31393171
[TBL] [Abstract][Full Text] [Related]
20. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
